Reuters logo
UPDATE 1-Shire boosts rare diseases business by buying Premacure
March 12, 2013 / 12:46 PM / 5 years ago

UPDATE 1-Shire boosts rare diseases business by buying Premacure

* Gets Phase II drug for eye disorder in premature babies

* Financial terms of Swedish acquisition not disclosed

LONDON, March 12 (Reuters) - Shire increased its investment in rare diseases on Tuesday by acquiring privately held Swedish biotech firm Premacure, which is developing a drug for a potentially blinding eye disorder in premature babies.

Britain’s third biggest drugmaker did not reveal how much it was paying for the Uppsala-based business but said it would pay a sum upfront followed by contingent payments based on clinical development and commercial success.

The acquisition takes Shire into the new area of neonatology - the treatment of sick or premature newborn infants - and expands its already substantial presence in rare diseases.

Treating diseases that affect only a small number of patients is a growing focus for many drug companies given the high prices that can be achieved.

Premacure, which was launched in 2006, has an experimental protein replacement medicine in mid-stage Phase II clinical development for the prevention of retinopathy of prematurity (ROP).

Normal full-term babies produce enough growth factors on their own to prevent diseases like ROP. But those born before 31 weeks may lack chemicals such as insulin-like growth factor 1 (IGF-1), which can result in life-long complications like ROP.

Shire said its human genetic therapies unit would continue with the Phase II study, the primary goal of which is to restore the IGF-1 levels in premature infants to those found in babies born at full term.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below